| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review Articles |
Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Turino, Italy
Requests for reprints: Carla Boccaccio, Division of Molecular Oncology, Institute for Cancer Research and Treatment, University of Turin Medical School, Str. Prov. 142, I-10060 Candiolo, Turin, Italy. Phone: 39-011-9933-208; Fax: 39-011-9933-225; E-mail: carla.boccaccio{at}ircc.it.
Blood coagulation disorders have been known to be associated with cancer for many years. However, the mechanisms responsible for their relationship have not been understood. Recent work indicates that activation of the MET oncogene, which drives invasion and metastasis in cancer, can promote a cancer-associated thrombohemorrhagic syndrome that is mediated by transcriptional up-regulation of the procoagulation factors plasminogen activator inhibitor type-1 and cyclooxygenase-2. These findings reveal a long-sought mechanistic link between coagulation and cancer, highlighting a clinically important perspective on malignant invasion and metastasis.
This article has been cited by other articles:
![]() |
A. Varki Trousseau's syndrome: multiple definitions and multiple mechanisms Blood, September 15, 2007; 110(6): 1723 - 1729. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Albini, D. M. Noonan, and N. Ferrari Molecular Pathways for Cancer Angioprevention Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |